Given the clinical need for novel biomarkers to improve the non-invasive screening and diagnostic approaches for steatosis/steatohepatitis, large and prospective studies are required to further explore this potential association of circulating ANGPTL8 to various stages of steatosis/steatohepatitis, and to elucidate its temporal/causal direction, particularly under the new MASLD diagnosis/term. The gene discussed is ANGPTL8; the disease is steatosis.